BI Invests in Cancer Vaccine Company Amal Therapeutics
Amal Therapeutics, a Swiss biotechnology company, has completed CHF 3 million ($3.1 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech GrÃ¼nderfonds also participated in the round which will help progress Amal's cancer vaccines.
Amal Therapeutics will use the funds to progress the preclinical development of its lead vaccine (ATP124) for colorectal cancer and to further develop its Kisma technology platform for therapeutic tumor vaccination. This technology is able to generate potent long-lasting anti-tumor immunity and avoid tumor immune escape, according to information from Boehringer Ingelheim.
Amal's vaccines combine a cell-penetrating peptide (CPP) with a multi-antigenic chimeric cargo with various CD8+ and CD4+ epitopes and a constitutive activator of dendritic cells, enabling them to simultaneously stimulate multi-epitopic cytotoxic T cell-mediated immunity, induce helper T (Th) cells, and promote immunological memory.
Amal was founded in 2012 as spin-off from the University of Geneva.
Source: Boehringer Ingelheim